efavirenz and uc-781
efavirenz has been researched along with uc-781 in 9 studies
Research
Studies (9)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (66.67) | 29.6817 |
| 2010's | 3 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Balzarini, J; Camarasa, MJ; Chamorro, C; Gago, F; Lobatón, E; Pelemans, H; Pérez, C; Pérez-Pérez, MJ; Rodríguez-Barrios, F; San-Félix, A; Velázquez, S | 1 |
| Jorgensen, WL; Rizzo, RC; Tirado-Rives, J; Wang, DP | 1 |
| Jorgensen, WL; Kroeger Smith, MB; Rizzo, RC; Smith, RH; Tirado-Rives, J; Udier-Blagović, M; Wang, DP; Watkins, EK | 1 |
| Kang, X; Kollman, PA; Kuntz, ID; Wang, J | 1 |
| Anderson, KS; Bailey, CM; Barreiro, G; Domaoal, RA; Guimarães, CR; Jorgensen, WL; Kim, JT; Wang, L | 1 |
| Anderson, KS; Bollini, M; Cisneros, JA; Jorgensen, WL; Spasov, KA | 1 |
| Ariën, KK; Augustyns, K; Cos, P; Dirié, B; Heeres, J; Joossens, J; Lewi, PJ; Lyssens, S; Maes, L; Michiels, J; Van der Veken, P; Vanham, G; Venkatraj, M | 1 |
| Balzarini, J; Burt, V; Carbonez, A; De Clercq, E; Kleim, JP | 1 |
| Ariën, KK; Heyndrickx, L; Michiels, J; Quiñones-Mateu, ME; Selhorst, P; Terrazas-Aranda, K; Vanham, G; Vazquez, AC; Vereecken, K; Weber, J | 1 |
Other Studies
9 other study(ies) available for efavirenz and uc-781
| Article | Year |
|---|---|
Identification of a putative binding site for [2',5'-bis-O-(tert-butyldimethylsilyl)-beta-D-ribofuranosyl]-3'-spiro-5''-(4''-amino-1'',2''-oxathiole-2'',2''-dioxide)thymine (TSAO) derivatives at the p51-p66 interface of HIV-1 reverse transcriptase.
Topics: Amino Acid Substitution; Anti-HIV Agents; Binding Sites; Cell Line; HIV Reverse Transcriptase; HIV-1; Humans; Models, Molecular; Molecular Conformation; Molecular Structure; Mutagenesis, Site-Directed; Protein Conformation; Protein Structure, Secondary; Protein Subunits; Recombinant Proteins; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; Spiro Compounds; Static Electricity; Structure-Activity Relationship; Thymidine | 2001 |
Antiviral drug design: computational analyses of the effects of the L100I mutation for HIV-RT on the binding of NNRTIs.
Topics: Drug Design; HIV Reverse Transcriptase; Models, Molecular; Mutation; Reverse Transcriptase Inhibitors | 2001 |
Prediction of activity for nonnucleoside inhibitors with HIV-1 reverse transcriptase based on Monte Carlo simulations.
Topics: Alkynes; Anilides; Benzoxazines; Computer Simulation; Cyclopropanes; HIV Reverse Transcriptase; Hydrogen Bonding; Models, Molecular; Monte Carlo Method; Nevirapine; Oxazines; Protein Binding; Quinoxalines; Regression Analysis; Reverse Transcriptase Inhibitors; Structure-Activity Relationship; Uracil | 2002 |
Hierarchical database screenings for HIV-1 reverse transcriptase using a pharmacophore model, rigid docking, solvation docking, and MM-PB/SA.
Topics: Allosteric Site; Anti-HIV Agents; Crystallography, X-Ray; Databases, Factual; Drug Design; HIV Reverse Transcriptase; Models, Molecular; Molecular Conformation; Molecular Structure; Protein Binding; Quantitative Structure-Activity Relationship; Reverse Transcriptase Inhibitors; Statistics as Topic; Thermodynamics | 2005 |
From docking false-positive to active anti-HIV agent.
Topics: Anti-HIV Agents; Cell Line; Databases, Factual; HIV Reverse Transcriptase; HIV-1; Humans; Ligands; Models, Molecular; Molecular Conformation; Oxadiazoles; Quantitative Structure-Activity Relationship; Reverse Transcriptase Inhibitors; Thermodynamics | 2007 |
Optimization of diarylazines as anti-HIV agents with dramatically enhanced solubility.
Topics: Anti-HIV Agents; Cell Line, Transformed; Cell Proliferation; Dose-Response Relationship, Drug; HIV-1; Humans; Hydrazines; Microbial Sensitivity Tests; Models, Molecular; Molecular Structure; Solubility; Structure-Activity Relationship | 2013 |
From human immunodeficiency virus non-nucleoside reverse transcriptase inhibitors to potent and selective antitrypanosomal compounds.
Topics: Anti-HIV Agents; Cell Line; Cell Survival; Dose-Response Relationship, Drug; HIV Reverse Transcriptase; HIV-1; Humans; Microbial Sensitivity Tests; Molecular Structure; Parasitic Sensitivity Tests; Reverse Transcriptase Inhibitors; Structure-Activity Relationship; Trypanocidal Agents; Trypanosoma brucei brucei; Trypanosoma brucei rhodesiense | 2014 |
Long-term exposure of HIV type 1-infected cell cultures to combinations of the novel quinoxaline GW420867X with lamivudine, abacavir, and a variety of nonnucleoside reverse transcriptase inhibitors.
Topics: Alkynes; Anilides; Anti-HIV Agents; Benzoxazines; Cell Line; Cyclopropanes; Delavirdine; Dideoxynucleosides; Dose-Response Relationship, Drug; Drug Combinations; Drug Resistance, Microbial; Furans; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Microbial Sensitivity Tests; Mutation; Nevirapine; Oxazines; Quinoxalines; Reverse Transcriptase Inhibitors; Thioamides; Uracil | 2000 |
Human immunodeficiency virus type 1 resistance or cross-resistance to nonnucleoside reverse transcriptase inhibitors currently under development as microbicides.
Topics: Alkynes; Anilides; Anti-Infective Agents; Benzoxazines; Cell Line; Cells, Cultured; Cyclopropanes; Delavirdine; Drug Resistance, Viral; Furans; Genotype; HIV-1; Humans; Nevirapine; Reverse Transcriptase Inhibitors; Thiazoles; Thioamides; Thiourea | 2011 |